CRISPR and Cancer

American researchers have used transcriptome-wide CRISPR-Cas13 screens in multiple human cell lines to identify 46 universally essential and more than...

The FDA has cleared HuidaGene Therapeutics' investigational new drug application for HG202, the first CRISPR-Cas13 RNA-editing therapy to enter...

Researchers in Italy and Australia report a triple combination strategy involving CRISPR that boosts the response of neuroblastoma to immunotherapy.

In this clinical update, we bring you the latest news from four gene-editing trials sponsored by RenJi Hospital (Shanghai), The University of Texas MD...

German scientists have presented a dual modification strategy that combines CRISPR-Cas9 and CAR technology to enhance the efficacy of natural killer...

Dual CAR-T cells incorporating an IF/THEN logic-gated system show enhanced anti-tumour cytotoxicity and reduced off-tumour effects in mouse models....

Last week, Vor Bio announced new, encouraging clinical data from the ongoing Phase 1/2 VBP101 trial of trem-cel followed by the anti-CD33...

Researchers in Italy report a new nanoplatform for IL-30 knockout as a novel therapeutic strategy for metastatic prostate cancer.